• Company
• The sales of Prolia & Evenity exceed ₩100 billion
• by Mar 10, 2022 05:53am

• Company
• Why the Patent Court rejected the ‘prodrug strategy’
• by Kim, Jin-Gu Mar 10, 2022 05:53am

• Policy
• Omicron's fatality rate is at the level of flu
• by Lee, Jeong-Hwan Mar 10, 2022 05:53am

• Policy
• Finding ways to utilize the Patent-approval linkage system
• by Lee, Hye-Kyung Mar 10, 2022 05:53am

• Company
• Keytruda for esophageal cancer indications is imminent
• by Eo, Yun-Ho Mar 8, 2022 06:08am

• Company
• Generation shift of ALK targeted drugs... rise of Alecensa
• by Mar 8, 2022 06:08am

• Company
• Domestic production of Sputnik V was delayed
• by Kim, Jin-Gu Mar 8, 2022 06:08am

• Policy
• The fatality rate of Omicron is low
• by Lee, Jeong-Hwan Mar 8, 2022 06:08am

• Policy
• DREC rejects reimb of neurofibromatosis drug ‘Koselugo'
• by Lee, Tak-Sun Mar 8, 2022 06:08am

• Company
• Changes in the lung cancer treatment market are detected
• by Mar 7, 2022 05:50am